Close Menu

Dana-Farber

The methods, both published in Nature Biotechnology this week, result in completely phased haplotypes, without the need for sequencing parental samples.

By identifying these biomarkers, the partners hope to better predict which SMM patients will progress to multiple myeloma and ultimately develop new treatments.

At the Association for Molecular Pathology annual meeting, cancer researcher William Hahn talked about efforts to map cancer fitness genes at the genome scale.

In Genome Biology this week: mouse model for determining immunotherapy response, genomic changes that occur with non-small cell lung cancer metastasis, and more.

Two new papers have identified thousands of genetic loci with ties to more than two-dozen blood cell traits in individuals from up to five ancestry groups.

Therapy was most effective in patients with a diverse baseline repertoire of T cell receptors and an associated expansion of singleton clones during treatment.

The company will provide proprietary algorithms for analyzing omics and imaging data to define predictors of drug response and identify new biomarkers.

The group's CureCloud initiative combines patient health data with sequencing data from its liquid biopsy test to help oncologists select treatments.

Transcription factor reprogramming during prostate cancer metastases appears to involve epigenetic changes that resemble those at play during prostate development, new research finds.

The single-cell RNA-sequencing analysis found that undifferentiated ependymomas are more likely to be linked to a poorer prognosis.

Pages

According to the Associated Press, genetic genealogy has helped law enforcement officials identify an unknown victim of the Green River Killer.

Imperial College London researchers are shifting away from testing a COVID-19 vaccine to focus on combating newly emerging SARS-CoV-2 variants, the Independent says.

In PNAS this week: target to reduce chemotherapy-induced cardiac injury, tool finds ancient endogenous RNA viruses, and more.

Moderna reports its vaccine is effective against new SARS-CoV-2 strains, though it is also developing a booster, according to the New York Times.